W2A‐28: a novel benzamide‐based dual modulator of class I HDACs and Wnt/ß‐catenin signaling for the treatment of Alzheimer's disease
Our studies suggest that W2A-28 is a potential drug candidate for the treatment of AD.
Authors
- Takahisa Kanekiyo (ORCID: https://orcid.org/0000-0001-6751-9374)
- GuoJun Bu
- Suren Jeevaratnam (ORCID: https://orcid.org/0000-0001-7556-6613)
- Thomas R. Caulfield (ORCID: https://orcid.org/0000-0002-1055-3069)
- Yonghe Li (ORCID: https://orcid.org/0000-0002-3134-3319)
- Wenyan Lu
Institutions
- WinnMed (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_100859
- Primary Topic
- Histone Deacetylase Inhibitors Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00